SMi present their inaugural conference on...

**IMMUNOGENICITY**
Assessing Early Risks, Clinical Implications, Outcomes and Tolerance of Immunological Response

Holiday Inn Regents Park, London, UK

**Conference Chairs:**
- Matthew Baker, Chief Scientific Officer, Antitope
- Martin Lechmann, Development DMPK Project Leader, Roche

**Key Speakers Include:**
- Robert Dodge, Associate Director, BMS
- Thomas Lee, Scientific Investigator, Clinical Immunology, GSK
- Takashi Kei Kishimoto, Chief Scientific Officer, Selecta Biosciences Inc.
- Ronit Mazor, Research Fellow, National Cancer Institute, National Institutes of Health
- Anne De Groot, CEO/CSO, EpiVax Inc
- Daniel Kramer, Associate Director, Project Representative NBE, Merck Serono

**BUSINESS BENEFITS FOR 2014:**
- Grasp an understanding of Immunogenicity and gain an insight into assessing early risks
- Hear case studies on the tools for consideration being utilised for the determination of immunogenicity
- Assess major hurdles in clinical development and the implications in design of biologic therapeutics
- Enhance your understanding on how to best evaluate read outs for immune response

**PLUS TWO INTERACTIVE HALF-DAY POST-CONFERENCE WORKSHOPS**
Wednesday 16th July, Holiday Inn Regents Park, London, UK

A: Clinical Impact of Immunogenicity and Predictive Tools
Workshop Leader:
Melody Sauerbom, Senior Expert Immunogenicity, TNO Triskelion
8.30am - 12.30pm

B: Immunogenicity of Biosimilars
Workshop Leaders:
John Chappell, Head of Immunoassay, CPR Pharma Services
Bracha Timan, Head of Global Bioassays and Technology, Teva Pharmaceuticals Ltd
1.30pm - 5.30pm

www.immuno.co.uk
Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711
ACADEMIC & GROUPS DISCOUNTS AVAILABLE
11.00 Tregitopes an Immunomodulation Powerhouse: Regulating Immune Responses to Biologicals
- Modulation of T cell responses in the context of protein therapy and inflammation may contribute to the design of improved biologic therapeutics for a wide range of clinical conditions.
- A critical flaw in most predictions of immunogenicity is the failure to factor regulatory T cell epitopes (Tregitopes) into the assessment.
- The presenter will provide several case studies that validate the critical importance of Tregitopes to biologics, including but not limited to protein replacement therapies, blood factor replacement therapies, monoclonal antibodies as well as mitigation of auto-inflammatory and autoimmune responses.

Anne De Groot, CEO/CSO, Epivax Inc.

11.40 Inducing Immunological Tolerance – reviewing the flip side
- Reviewing the problem of immunogenicity and asking why a protein is immunogenic in certain individuals and not others?
- What do we understand about immunological tolerance?
- Can proteins be modified to become less immunogenic?
- Designing peptides that switch off immune responses and promote tolerance.

David Wraith, Professor of Experimental Pathology, University of Bristol

12.20 Networking Lunch and Poster Presentation Session

1.30 Human In Vitro models to assess immunogenicity
- The application of human In Vitro models during early drug development
- Technical challenges and standardisation of In Vitro models
- Relevance of In Vitro models

Chloe Ackaert, Scientific Researcher, University of Salzburg

2.10 Identifying and removing T cell epitopes in immunotoxins
- Immunotoxins are therapeutic proteins that are used to treat cancer. Immunogenicity is their main stumbling block in the clinic.
- Assessing comprehensive experimental methods to identify and eliminate the T cell epitopes in the immunotoxin.
- Designing a new immunotoxin that has significantly diminished T cell immunogenicity and yet an excellent anti-tumor effect.

Ronit Mazor, Research Fellow, National Cancer Institute, National Institutes of Health

2.50 Generation of non-immunogenic proteins with full biological activity
- Many factors either associated with the product, patient, route of delivery or formulation etc. can contribute to immunogenicity but CD4+ T cell epitopes are the principal drivers of immunogenicity in vivo.
- Frequency of CD4+ T cell response in ex vivo human T cell assays such as EpiscreenTM gives good correlation with clinical-stage ADA thus providing an important tool for protein engineering.
- Deimmunisation of antibodies and proteins focuses on removal of peptide binding to human MHC class II; can be supplemented by other strategies.
- CD4+ T cell epitopes can be successfully removed from complex non-human proteins whilst minimising loss of activity.

Matthew Baker, Chief Scientific Officer, Antitope

3.30 Afternoon Tea

Topic: What are the fundamental aspects of the mechanisms of tolerance?

4.00 Nanoparticles for the Induction of Immunological Tolerance
- Selecta has developed biodegradable nanoparticles capable of inducing antigen-specific immune tolerance.
- We have demonstrated inhibition of anti-drug antibodies to biologic therapies, such as Factor VIII and adalimumab, resulting in improved efficacy and safety in animal models.
- Tolerogenic nanoparticle technology can be applied to existing biologic drugs as part of a lifecycle management strategy to maintain or enhance market share and to novel drugs in development to improve probability of success and differentiate from competitors.

Takashi Kei Kishimoto, Chief Scientific Officer, Selecta Biosciences Inc.

4.40 Chairman’s Closing Remarks and Close of Day One

SPONSORSHIP AND EXHIBITION OPPORTUNITIES
Smi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your company’s marketing strategy. Prime networking opportunities exist to entertain, enhance and expand your client base within the context of an independent discussion specific to your industry. Should you wish to join the increasing number of companies benefiting from sponsoring our conferences please call: Alia Malick, Director on +44 (0) 20 7827 6168 or email: amalick@smi-online.co.uk
IMMUNOGENICITY
Day Two | Tuesday 15th July 2014

8.30 Registration & Coffee

9.00 Chairpersons Opening Remarks
Martin Lechmann, Development DMPK Project Leader, Roche

CLINICAL IMPLICATIONS AND OUTCOMES

9.10 Case Studies on Pre-Existing Antibodies
- Pre-existing antibodies in treatment-naïve subjects have been often detected during clinical ADA assessments. However, limited information on prevalence, physiological effect, and impact on post-treatment ADA induction is available.
- This talk will address pre-existing antibody characterization and implications for immunogenicity management and strategies during clinical studies.
Thomas Lee, Scientific Investigator, Clinical Immunology, GSK

KEYNOTE ADDRESS

9.50 Case Study: Immunogenicity testing for Biosimilars - One assay versus two assays
- Assessing the implications of screening of early compounds
- Evaluating the consequences of immunogenicity in clinical development testing
- Assessing strategies and considerations for clinical trial design.
Robert Dodge, Associate Director, BMS

10.30 Morning Coffee

IMMUNOGENICITY OF BIOSIMILARS

11.00 Immunogenicity testing for Biosimilars - One assay versus two assays - A case study
- Immunogenicity is one major hurdle in the development of Biosimilars
- There is an ongoing debate about if one has to develop and validate dedicated immunogenicity assays for the Originator and the Biosimilar or if one assay can be employed.
- The talk will present the approach Merck Serono is currently using for their Biosimilar program.
Daniel Kramer, Associate Director, Project Representative NBE, Merck Serono

11.40 Immunogenicity Analytical considerations when supporting Biosimilar Drug Development
- Presentation will assess what Immunogenicity assays that need to be developed in support of Biosimilar Clinical Development
- Some of the considerations include choice of methodology, Development of 1 Assay v 2 Assays, Positive controls, Neutralising Assays
- Presentation will include case study data.
John Chappell, Head of Immunoassay, CPR Pharma Services

12.20 Networking Lunch and Poster Presentation Session

IMMUNOGENICITY DEVELOPMENTS

1.30 KEYNOTE ADDRESS
Insight into the development of Biologic Therapeutics
- Understanding the principles of immunogenicity testing during product development
- Reviewing the pharmacokinetic and efficacy effects of biologic therapeutics.
Martin Lechmann, Development DMPK Project Leader, Roche

2.10 Novel Methods to Induce Tolerance for Adverse Immune Reactions
- Immune tolerance mechanisms versus reducing immunogenicity
- Application of B cell presentation for tolerance
- Fc fusion proteins and the role of IgG epitopes
- Application of specific T regulatory cells to control immune responses.
David Scott, Professor and Vice Chair for Research, Uniformed Services University of Health Science

2.50 Afternoon Tea
Topic: Do you fight antibodies with antibodies?

3.20 Predictive/preclinical Immunogenicity Risk Mitigation: Sense and non-sense
- Unwanted immunogenicity is a critical hurdle during drug development
- Assessing immunogenicity at an early stage can significantly reduce the risk of failure later on.
- Standardisation and regulation of early assessment tools.
Philippe Stas, Consultant, BLA Consult

4.00 Predictability using pre-clinical tools
- What is classed as important in the decision making process?
- Is the replacement of animals a way of assessing immunogenicity?
- How important are cell based assays when assessing neutralisation of ligand binding assays?
- Evaluating the translation value and whether a minimal approach should be utilised up until phase II/III.
Chloe Ackaert, Scientific Researcher, University of Salzburg Ronit Mazor, Research Fellow, National Cancer Institute, National Institutes of Health
David Scott, Professor and Vice Chair for Research, Uniformed Services University of Health Science

4.40 Chairman’s Closing Remarks and Close of Day Two
Overview of workshop:
This workshop will focus on the clinical impacts of immunogenicity on safety and efficacy with example cases. In addition, Immunogenicity strategies during clinical stages will be discussed including the risk-assessment of biologics. A short intro into bioassays and the importance to measure neutralizing antibodies will be presented. Last, but not least current overview of predictive immunogenicity tools will be given and the question, “What translational value do the data from preclinics have to the clinical situation?” will be discussed.

Key Benefits of Attending:
This workshop will bring all of the aspects of immunogenicity learned during the conference in perspective with a focus on clinical impacts of immunogenicity.

Programme:
8.30 Registration and coffee
9.00 Immunogenicity: Overview Clinical Impacts
9.30 The tiered approach
10.30 Coffee Break
11.00 The risk assessment approach and what that means for each clinical phase
11.30 Translational value of preclinical data
12.30 Close of Workshop

About the workshop host:
Dr. Sauerborn spent most of her undergrad years in well-known institutes such as the Centers for Disease Control and Prevention in Atlanta to widen her knowledge in immunology. After acquiring her Masters in Science she joined the lab of Prof. Schellekens and Prof. Jiskoot, two experts in immunogenicity of protein drugs, to shed more light on the immunological aspects of antibody formation against aggregated protein therapeutics. After obtaining her PhD she started a spin-off, ADA InVivo BV, a biotech CRO in the field of drug safety. Currently she is a project leader, trainer and senior expert in immunogenicity at the bioanalysis and immunogenicity department at TNO Triskelion BV, a Dutch CRO.
Overview of workshop:
The workshop will explore the analytical requirements for developing and validating assays in support of Preclinical and Clinical Biosimilar Drug Development. The main focus will be on the Immunogenicity assay requirements but the requirements for PK and Biomarker assays will also be discussed. This will be detailed analysis of both the regulatory and clinical requirements for immunogenicity assessment. The workshop will present Case studies on how assays have been developed and validated in support of Biosimilar drug Development.

Why you should attend:
• To get an understanding of the clinical and regulatory considerations for immunogenicity assessments
• To get an understanding on how immunogenicity assays can be developed and validated for Biosimilar Drug development
• See data from actual Case Studies

Programme:
1.30 Registration and coffee
2.00 Importance of Immunogenicity Assessments
• Clinical Considerations
2.30 Immunogenicity Rates for the originator
• PK Profile
• Disease populations
• Risk Based strategy
3.00 Afternoon Tea
3.30 Regulatory Guidances and White Papers
• EMA and FDA Guidances
• Industry White Papers
• AAPS Biosimilar APC committee
In-vitro Immune Stimulation Assays
Screening and Confirmatory Assays
• What Assays to use
• Development of 1 Assays v 2 Assays
• Positive Control Selection
• Calculation of Cut Points
• Statistical Requirements (do you need a Biostatistician?)
• Drug Tolerance
• Sensitivity
• Stability
Neutralising Assays
• Choice of Assays
• Functional Assays v Competition Ligand Binding
4.30 PK Assays in support of Biosimilar Development
• Biomarker Assays in support of Biosimilar Development
5.30 Close of Workshop

About the workshop host:
Prior to joining CPR Pharma Services, John Chappell worked for more than 20 years with leading CROs in both, Europe and North America. As a leading expert in ligand binding assay development, validation and implementation, John is a member of the AAPS Committee that is preparing white papers on biosimilar bioanalytical support, including pharmacokinetic analysis and immunogenicity assessments.

A highly experienced professional, John leads a team of analytical scientists providing a ligand binding assay service for biomarkers, monoclonal antibodies, biosimilars and biologics in early and late phase clinical trials.
IMMUNOGENICITY

4 WAYS TO REGISTER

ONLINE www.immuno.co.uk

FAX your booking form to: +44 (0) 870 9090 712
PHONE on: +44 (0) 870 9090 711

POST your booking form to: Events Team, SMI Group Ltd, 2nd Floor South, Harling House, 47-51 Great Suffolk Street, London, SE1 0BS, UK

EARLY BIRD DISCOUNT □ Book by 31st March to receive £300 off the conference price

CONFERENCE PRICES

| GROUP DISCOUNTS AVAILABLE
<table>
<thead>
<tr>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>I would like to attend: (Please tick as appropriate) Fee Total</td>
</tr>
<tr>
<td>□ Conference &amp; 2 Workshops £2697.00 + VAT £3334.40</td>
</tr>
<tr>
<td>□ Conference &amp; 1 Workshop £2098.00 + VAT £2517.60</td>
</tr>
<tr>
<td>□ Conference only £1499.00 + VAT £1798.80</td>
</tr>
<tr>
<td>□ 1 Workshop only £599.00 + VAT £718.80</td>
</tr>
<tr>
<td>□ 2 Workshops only £1198.00 + VAT £1437.60</td>
</tr>
</tbody>
</table>

PROMOTIONAL LITERATURE DISTRIBUTION

| □ Distribution of your company’s promotional literature to all conference attendees £999.00 + VAT £1198.80 |

The Conference fee includes refreshments, lunch, conference papers and access to the document portal containing all of the presentations.

LIVE STREAMING/ON DEMAND/DOCUMENTATION

<table>
<thead>
<tr>
<th>Unable to travel, but would like to watch the conference live, ask questions, participate as if you were in the room?</th>
</tr>
</thead>
<tbody>
<tr>
<td>□ Live Streaming £999.00 + VAT £1198.80</td>
</tr>
<tr>
<td>□ On demand (available 24 hours after the event) £599.00 + VAT £718.80</td>
</tr>
<tr>
<td>□ Access to the conference documentation on the Document Portal £499.00 + VAT £598.80</td>
</tr>
<tr>
<td>□ The Conference Presentations – paper copy (or only £300 if ordered with the Document Portal) £499.00</td>
</tr>
</tbody>
</table>

PAYMENT

Payment must be made to SMI Group Ltd, and received before the event, by one of the following methods quoting reference P-110 and the delegate’s name. Bookings made within 7 days of the event require payment on booking, methods of payment are below. Please indicate method of payment:

| □ UK BACS Sort Code 300009, Account 00936418 |
| □ Cheque We can only accept Sterling cheques drawn on a UK bank. |
| □ Credit Card □ Visa □ MasterCard □ American Express |

All credit card payments will be subject to standard credit card charges.

Card Number: ____________________________ Expiry Date: ____________________________

Cardholder’s Name: ____________________________

Signature: ____________________________ Date: ____________________________

VENUE

Holiday Inn Regents Park, Carburton St, London W1T 5EE

Please contact me to book my hotel Alternatively call us on +44 (0) 870 9090 711. email: hotels@smi-online.co.uk or fax +44 (0) 870 9090 712

Terms and Conditions of Booking

Payment: If payment is not made at the time of booking, then an invoice will be issued and must be paid immediately and prior to the start of the event. If payment has not been received then credit card details will be requested and payment taken before entry to the event. Bookings within 7 days of event require payment on booking. Access to the Document Portal will not be given until payment has been received.

Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another delegate to take your place at any time prior to the start of the event. Two or more delegates may not share one place at an event. Please make sure bookings are for each delegate separately.

Cancellation: If you wish to cancel your attendance at an event and you are unable to send a substitute, then we will refund/cancel 50% of the fee less a £50 administration charge, providing that cancellation is made in writing and received at least 28 days prior to the start of the event. Regrettably cancellation after this time cannot be accepted. We will however provide the conference documentation via the Document Portal to any delegate who has paid but is unable to attend for any reason. Due to the interactive nature of the Belfilm we are not normally able to provide documentation in these circumstances. We cannot accept cancellations of orders placed for Documentation or the Document Portal as these are reproduced specifically for you. If you have to cancel the event for any reason, then we will make a full refund immediately, but demand any further liability.

Attention: It may become necessary for us to make alterations to the content, speakers, timing, venue or date of the event compared to the advertised programme.

Data Protection: The SMI Group gathers personal data in accordance with the UK Data Protection Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about other products and services. Unless you tick here ☐ we may also share your data with third parties offering complementary products or services if you have any queries or want to update any of the data that we hold then please contact our Database Manager on databaseadmin@immuno.co.uk or visit our website www.smi-online.co.uk updates quoting the ID no. that was detailed above your address on the attached letter.

If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email them at events@smi-online.co.uk